Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous abatacept in children and adolescents with active polyarticular juvenile idiopathic arthritis
2012-003195-39Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2013
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of abatacept in polyarticular juvenile idiopathic arthritis and juvenile idiopathic arthritis (JIA), sponsored by Bristol Myers Squibb. Primary endpoint: Abatacept steady-state trough concentration at Day 113. Started Jul 2013; status: completed.
02
Drugs
abatacept
03
Conditions
polyarticular juvenile idiopathic arthritisjuvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2012-003195-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003195-39.